Libre Pathology talk:Study Group - Revision history

Tate at 13:29, 12 August 2015

2015-08-12T13:29:46Z

← Older revision		Revision as of 13:29, 12 August 2015
Line 49:		Line 49:

	= [[Short answer questions submitted by Tate]]=		= [[Short answer questions submitted by Tate]]=

	~~== Short answer questions on genetics and molecular pathology. ==~~

	~~These are some questions I came up with that are plausible to me... let me know if they are out to lunch.~~

	~~==[[Molecular Pathology Rotation Notes]]==~~

	~~==[[Robbins and Cotran 9th Edition Questions]]==~~

	~~==[[Cytogenetics Review Questions]]==~~


	~~== Molecular Genetic Diagnosis==~~
	~~{{hidden\|List three basic molecular diagnostic techniques\|a. Karyotyping, b. Southern blot, c. Sanger DNA sequencing, d. Polymerase chain reaction}}~~


	~~===CAP Molecular Diagnosis of Lung Cancer===~~

	{{hidden\|List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration\|1. 100% of CML: BRR-ABL > Imatinib, 2. 20% of Lung Adenocarcinoma: EGFR > Erlotinib/Gefitinib, 3. 25% Infiltrative ductal carcinoma of breast HER2>Trastuzumab, 4. 50% of Melanoma, BRAF v600E > PLX4032, 5. 4% of Lung Adenocarcinoma: ALK > Crizotinib}}

	~~{{hidden\|List and describe 5 areas of Genetic characaterization of tumours for personalized medicine\|DNA mutations, DNA chromosomal alterations, mRNA and MiRNA profiling, Proteomics, DNA epigenetics}}~~

	~~{{hidden\|What fraction of Lung adenocarcinomas have no known detactable mutations\|42%}}~~

	~~{{hidden\|What are the three most common molecular alterations of Lung Adenocarcinoma\|KRAS 23%, EGFR 15%, TP53 5%}}~~

	~~{{hidden\|What is the two most common molecular alteration makes patients with EGFR mutations resistant to targetted therapies?\|KRAS (primary) and T790M (primary and acquired)}}~~

	~~{{hidden\|List two EGFR kinase inhibitors.\|Gefitinib/Iressa, Erlotinib/Tarceva}}~~

	~~{{hidden\|What are the three most common cancers associated with KRAS mutations?\|Pancreatic 90%, Colon 50%, Lung NSCLC 30%}}~~

	~~{{hidden\|Why don't KRAS + tumours respond to Anti EGFR therapies?\|KRAS is downstream from EGFR, so changing the function of EFGR would not have any effect on mutated KRAS}}~~

	~~{{hidden\|Explain the cost effectiveness of genetic testing for targetted therapies?\|Most molecular tests cost $200-1000, vs one month of targetted therapy $2000-10000/month}}~~

	{{hidden\|What are the three most common cancers associated with BRAF mutations?\|Melanoma 70%, Papillary Thyroid Carcinoma 50%, Ovarian serious carcinoma 30%, Colon cancer 10%, Hint Papillary architecture}}

	{{hidden\|Beta catenin/CTNNB1 expression is found with which histological pattern of lung adenocarcinoma?\|Low grade adenocarcinoma of fetal type, poor px, <40yo, and has glycogen rich glandular formations, may occur in FAP patients}}

	~~{{hidden\|What is the most common ALK rearrangement found in NSCLC?\|EML4-ALK (90% of the 13% of lung cancers found to due to ALK fusions)}}~~

	{{hidden\|List some pros and cons of ALK FISH.\|Pros: commercial FDA approved probes available, not too expensive, moderately easy to disseminate screening, clinically validated, and failed tests on poorly preserved tissues are not reported as negative. Cons: need fish lab expertise (including pathologist and PhD), can be tricky if genes are close}}

	{{hidden\|List some pros and cons of ALK IHC.\|Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control}}

	~~{{hidden\|What is a positive count in the ALK-FISH?\|Signal split >2 probe diameters}}~~

	~~===CAP Molecular Diagnosis of AML===~~

	~~{{hidden\|List 6 genes associated with Acute Myeloid Leukemia that have been identified by cloning translocation break points\|RUNX1, RUNX1T1, PML, CBFB, ETV6, MLL}}~~

	{{hidden\|List the 5 main categories of classification of Acute Myeloid Leukemia\|1. AML with recurrent genetic abnormalities, 2. AML with myelodysplasia-related changes, 3. Therapy related myeloid neoplasms, 4. AML, NOS, 5. Myeloid sarcoma}}

	~~{{hidden\|Give any three translocations identified in AML.\|t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA}}~~

	{{hidden\|What entities are fall under the AML, NOS classification?\|AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis}}

	~~{{hidden\|List 2 genes which confer a poor prognostic impact vs 2 which confer a good prognostic impact.\|Poor: KIT, FLT3, Good: NPM1, CEBPA}}~~


	~~=== CAP Breast Cancer and Molecular ===~~

	~~{{Hidden\|List 3 patient and 4 tumour features that affect Prognosis and treatment.\|Patient: age, menstual status, comorbidities; Tumour factors: N status, LVI, size, grade}}~~

	{{hidden\|Describe the histological grading system used for breast cancer.\|Nuclear pleomorphism, mitoses, and mitotic index (each scored 1-3), with cumulative grade 1(score 3-5), grade 2(score 6-7), and grade 3 (score 8-9)}}

	~~{{hidden\|Describe the genomic grading system used for breast cancer.\|Low grade path (+1q, -16q), High grade (17q12, 11q13, nad 1p21-p25)}}~~

	~~{{hidden\|What defines a positive ER by IHC for the purpose of determining Tamoxifen therapy?\|>=1% of invasive tumour cells nuclear positivity}}~~

	~~{{hidden\|what defines a positive HER2 for the purpose of treatment with Herceptin?\|HER2 IHC >30% with complete membranous staining OR HER2/CEP17 >2.2}}~~

	~~{{hidden\|What are the indications for chemotherapy for breast cancer patients?\|Low expression of ER/PR, Grade 3 histology, Ki67>20%, 4+ nodes positive, +LVI, and tumour >5cm]}}~~

	~~{{hidden\|What are the indications for hormonal therapy alone?\|high expression of ER, Grade 1, Ki67>40%, Node negative, LVI not identified, and tumour 1-2cm}}~~

	~~{{hidden\|What are the four categories of breast cancer using the molecular classification of gene expression?\|Luminal A, Luminal B, Basal, and Her2 OverExpression}}~~

	{{hidden\|What is the difference between unsupervised and supervised molecular classification of tumours?\|Supervised is based on seperating patients by clinical features (e.g. progression) and trying to identify common molecular characteristics within those groups. Unsupervised is the opposite, tumours are grouped by common molecular features and their behaviour examined based on these groups.}}

	{{hidden\|What are the four groups and list one gene for each used in the Oncotype Dx 21 Gene prognostic model.\|Invasion (Cathespin L2, Stromolysin), HER2 (Her2, GRB7), ER (BCL2, SCUBE2, ER, PR), Proliferation (Cyclin D1, Ki67, MYBL2, STK15, Survivin)}}

	{{hidden\|What are the features of Luminal A breast cancer?\|High ER/PR expression, low histological grade, low levels of proliferative genes, HER2neg, indolent clinical course, better prognosis, Tamoxifen responders, low recurrence score Oncotype Dx, minimal benefits of adjuvant chemotherapy.}}

	{{hidden\|What are the features of Luminal B breast cancer?\|low ER/PR expression (may be PR neg), over expression GFR(Her2 & EGFR), higher histological grade, more aggressive clinical course, worse prognosis, more likely positive lymph nodes, and high expression of proliferative genes (Ki67)}}

	{{hidden\|What are the features of Luminal B HER2\| ER+, HER2+, agressive clinical course, decrease response to tamoxifen, may benefit from chemo and tamoxifen, increased recurrence risk Oncotype Dx Score, some may benefit form Herceptin+Chemo+Tamoxifen}}

	{{hidden\|What are the features of Her2 Enriched breast cancers?\| GEP are ER neg, over expression of other genes in HER2 aplification, high proliferative index, increased probability of P53 mutation, high histological grade, younger age, agressive clinical course, Poor Px, good response to herceptin in combination with chemo, pathological complete response to chemo+herceptin}}


	~~{{hidden\|What are the features of Basal breast cancer?\|}}~~

Tate at 13:25, 12 August 2015

2015-08-12T13:25:20Z

← Older revision		Revision as of 13:25, 12 August 2015
Line 48:		Line 48:
	[[User:Michael\|Michael]] ([[User talk:Michael\|talk]]) 23:43, 25 October 2014 (EDT)		[[User:Michael\|Michael]] ([[User talk:Michael\|talk]]) 23:43, 25 October 2014 (EDT)

	=== Short answer questions submitted by Tate ===		= [[Short answer questions submitted by Tate]]=

	== Short answer questions on genetics and molecular pathology. ==		== Short answer questions on genetics and molecular pathology. ==

Tate at 00:13, 28 July 2015

2015-07-28T00:13:20Z

← Older revision		Revision as of 00:13, 28 July 2015
Line 47:		Line 47:

	[[User:Michael\|Michael]] ([[User talk:Michael\|talk]]) 23:43, 25 October 2014 (EDT)		[[User:Michael\|Michael]] ([[User talk:Michael\|talk]]) 23:43, 25 October 2014 (EDT)

			=== Short answer questions submitted by Tate ===

	== Short answer questions on genetics and molecular pathology. ==		== Short answer questions on genetics and molecular pathology. ==

Tate: /* Molecular Genetic Diagnosis */

2015-05-22T15:48:25Z

Molecular Genetic Diagnosis

← Older revision		Revision as of 15:48, 22 May 2015
Line 60:		Line 60:

	== Molecular Genetic Diagnosis==		== Molecular Genetic Diagnosis==
	{{hidden\|List three basic molecular diagnostic techniques\|[[a. Karyotyping, b. Southern blot, c. Sanger DNA sequencing, d. Polymerase chain reaction}}		{{hidden\|List three basic molecular diagnostic techniques\|a. Karyotyping, b. Southern blot, c. Sanger DNA sequencing, d. Polymerase chain reaction}}

Tate at 10:56, 21 May 2015

2015-05-21T10:56:57Z

← Older revision		Revision as of 10:56, 21 May 2015
Line 55:		Line 55:

	==[[Robbins and Cotran 9th Edition Questions]]==		==[[Robbins and Cotran 9th Edition Questions]]==

			==[[Cytogenetics Review Questions]]==

Tate at 14:22, 19 May 2015

2015-05-19T14:22:50Z

Tate at 14:26, 18 May 2015

2015-05-18T14:26:49Z

← Older revision		Revision as of 14:26, 18 May 2015
Line 56:		Line 56:
	==[[Robbins and Cotran 9th Edition Questions]]==		==[[Robbins and Cotran 9th Edition Questions]]==

	~~{{hidden\|MC cause of spontaneous abortion is ?\|<center>[[ A demonstrable chromosomal abnormality.]]</center>}}~~

	~~{{hidden\|1% of all newborn infants possess a gross chromosomal abnormality and 5% of people <25y present with \|<center>[[a genetic disease. ]]</center>}}~~

	~~{{hidden\|Mutation\|<center>[[permanent change in the DNA, if affect germ cells are transmitted to the progeny ]]</center>}}~~

	{{hidden\|List and describe 4 broad categories of human genetic disorders:\|<center>[[Disorders related to mutation sin single genes with large effects i. Usually follow classic Mendelian pattern of inheritance
	~~ii. Often highly penetrant (large proportion of pop with gene has disease)~~
	~~b. Chromosomal disorders~~
	~~i. Structural or numerical alterations in autosomes and sex chromosomes~~
	~~ii. Uncommon, high penetrance~~
	~~c. Complex multigenic disorders~~
	~~i. Interactions between multiple variant forms of genes and environmental factors (polymorphisms), poly genic means disease when many polymorphism present~~
	~~d. Single gene disorders with nonclassic patterns of inheritance (not mendelian)~~
	~~i. Disorders resulting from triplet repeat mutations~~
	~~ii. Mutations in mitochondrial DNA~~
	~~iii. Those influenced by genomic imprinting~~
	~~iv. Those influenced by gonadal mosaicism]]</center>}}~~

	{{hidden\|List and describe the possible outcomes of a point mutation in a coding region?\|[[a. Missense mutation – pt mutation changes amino acid code, conservative when the amino acid is preserved, non conservative when replaced with another amino acid, b. Nonsense mutation – makes a stop codon ]]</center>}}

	{{hidden\|List and describe the possible outcomes of point mutation or deletion in a non-coding region.\|<center>[[a. Promoters/enhancers – interfere with binding of transcription factors, marker reduction or total lack of transcription, b. Introns – defective splicing > failure to make mature RNA > no translation]]</center>}}

	{{hidden\|List and describe the possible outcomes of deletions and insertions.\|<center>[[a.Small coding: not multiple of three = frameshift, if multiple of 3 than add or del amino acids accordingly, often premature stop codon
	~~i. Tay Sachs disease: 4 base pair insertion in Hexosaminidase A gene ]]}}~~

	{{hidden\|List and describe the possible outcomes of trinucleotide repeat mutations.\|[[a. Usually G&C, dynamic and increase during gametogenesis, “RNA stutters”,b. Fragile X – CGG 250-4000, Huntinton’s Disease ]]}}

	{{hidden\|List and describe three examples of inheritance of single gene mutations\|[[a. AD – manifested in the heterologous state, one parent of index case is usually affected, males and females affected and both can transmit conditioni. De novo cases may not have affected parentii. Penetrance = fraction of people with gene who have the traitiii. Variable expressivity = those with mutant gene have variety of phenotypesiv. Often age of onset is delayed so can reproduce before die from diseasev. Biochem mechanisms1. Reduced production of a protein or dysfunctional/inactive protein2. Involved in regulation of complex metabolic pathyway subject to feedback inhibition3. Key structural proteins (collagen and cytoskeleton of RBC)a. May be a dominant negative , e.g. osteogenesis imperfecta4. Gain of function are rare, 2 formsa. Increased in proteins normal function (excess enzyme activity)b. Huntinton’s diseas (abn protein accumulates, toxic to neurons)b. ARi. Largest category – both alleles at a locus are mutated1. Expression is uniform, complete penetrance common, early onset, unaffected carrier family members, mostly enzymesc. X Linkedi. All sex linked, and almost all are recessive , if Y Chromosome affected usually infertile males > no progenyii. Male expression b/c hemizygous, daughter carriers with variable phenotype because of lionization of 2nd X e.g G6DPiii. Dominant . vitamin D resistant rickets]]</center>}}

	~~Stopped at P142~~

	=== Molecular Genetic Diagnosis===		=== Molecular Genetic Diagnosis===

Tate at 14:21, 18 May 2015

2015-05-18T14:21:52Z

← Older revision		Revision as of 14:21, 18 May 2015
Line 54:		Line 54:
	==[[Molecular Pathology Rotation Notes]]==		==[[Molecular Pathology Rotation Notes]]==

	==Robbins and Cotran ~~Chapter 5~~ 9th Edition:==		==[[Robbins and Cotran 9th Edition Questions]]==

	{{hidden\|MC cause of spontaneous abortion is ?\|<center>[[ A demonstrable chromosomal abnormality.]]</center>}}		{{hidden\|MC cause of spontaneous abortion is ?\|<center>[[ A demonstrable chromosomal abnormality.]]</center>}}

Tate at 14:20, 18 May 2015

2015-05-18T14:20:07Z

← Older revision		Revision as of 14:20, 18 May 2015
Line 53:		Line 53:

	==[[Molecular Pathology Rotation Notes]]==		==[[Molecular Pathology Rotation Notes]]==

	~~===UNIT 1===~~

	~~{{hidden\|List three differences between DNA and RNA.\|[[DNA (double stranded, thymine, deoxyribose, more stable; RNA single stranded, ribose, uracil]]}}~~

	~~{{hidden\|What are the three stop codons?\|[UAA, UGA, UAG]]}}~~

	~~{{hidden\|Where does transcription begin?\|[[promoters at the 5' end before the coding region]]}}~~

	~~{{hidden\|List 2 enzymes necessary for transcription and their function. \|[[helicase, polymerase]]}}~~

	~~{{hidden\|List and describe three post transcription modifications of RNA.\|[[Splicing, cappping, 3'polyadenylation, ]]}}~~

	{{hidden\| Why is alternative splicing important?\|[[Using the basic construction blocks of coding sequences allows a large variety of recombinations, more efficient coding (e.g. creating functions to call))]]}}

	{{hidden\|List three differences between somatic and germline mutations. \|<center>[[Somatic: not passed on to progeny, only tumour or particular tissue cells with mutation, Germline: passed onto progeny, all cells have mutation * unless mosaicism or chimerism]]</center>}}

	{{hidden\|What is the difference between a missense and a non-sense mutation?\|<center>[[Missense the new base pair does not change the amino acid found in the protein at that location, non-sense changes the amino acid in the protein at that location]]</center>}}

	{{hidden\|Define a frameshift mutation. \|<center>[[deletion of a non-multiple of 3 which causes all further trinucleotide combinations to no longer code for the correct amino acid, often results in a premature stop codon]]</center>}}

	~~{{hidden\|Why are inversion mutations difficult to detect?\|<center>[[When the are smal, e.g. only a few base pairs]]</center>}}~~

	{{hidden\|Describe the potential sequelae of a translocation mutation. \|<center>[[when a segment on one chromosome is transferred to another, make a gene non-functional or can result in a fusion gene]]</center>}}

	~~===UNIT 2===~~
	~~{{hidden\|Translate the following: c.1524_1527delCGTA.\|<center>[[a small deletion of CGTA between the 1524 and 1527 base pairs]]</center>}}~~

	{{hidden\|List 5 features of SNPs.\|[[Most common DNA sequence variation in humans, must occur in >=1% of a particular population, frequency of SNPs varies by groups, but responsible for >90% of human genetic variation, an can be found in any region of genome]]}}

	{{hidden\|Define a regulatory SNP versus a synonymous SNP?\|[[Regulatory SNP: occur in non-coding regions e.g. promoters where they affect mRNA expression and stability, as occur in the splice site where can result in abnormal protein production]]}}

	{{hidden\|What is the difference between a microstalellite and a minisattelite?\|<center>[[Microsatellite = stretches of DNA with sequences of 2-4 base pairs repeated a few dozen times (STRP), minisatellite = variable number of tandem repeats 10-100bp in lenght]]</center>}}

	~~{{hidden\|Describe Hardy-Weinberg Equilibrium?\|<center>[[Mathematical probability function to describe allelic and genotype frequency in a random mating scenario]]</center>}}~~

	~~{{hidden\|What factors can disrupt the H-W equilibrium?\|<center>[[non random mating, migration, genetic drift, founder effects, mutation, natural selection]]</center>}}~~

	{{hidden\|What is linkage disequilibrium?\|<center>[[The closer two genes are together on the chromosome the more likely they are to be found toghether in a population, during meiosis some exchange of material happens between the two chromosomes]]</center>}}

	~~===UNIT 3===~~
	~~{{hidden\|What are the three major steps of PCR?\|<center>[[denaturing, primer annealing, strand extending]]</center>}}~~

	{{hidden\|What is the hallmark of PCR?\|<center>[[The cycling at different temperatures, in the presence of key reaction components to traget and exponentially amplify a specific DNA target sequence]]</center>}}

	{{hidden\|What factors affect the method of genotyping chosen?\|<center>[[throughput, type of variants that can be genotyped, equipment and costs, TAT, technical expertise, and multiplex ability]]</center>}}

	{{hidden\|Define sensitivity, specificity, positive predictive value and negative predictive value. \|<center>[[Sensitivity = probability of a positive test in a disease, specificity = probability of a negative dest in a non-diseased patient ]]</center>}}

	{{hidden\|Define reproduciblity and accuracy of an analytical test. \|<center>[[Reproducability = probability of the test repeatedly producing the same reults in the same person, Accuracy = the degree to which the observed genotype matches the true genotype]]</center>}}

	{{hidden\|Describe briefly Sanger sequencing.\|<center>[[DIdeoxynucleotides are used in a mix with deoxynucleotides, the Di*** terminate the chain, and so you get all possible lengths of chains so then you put them all in order and you can read (based on weight) which one is at each position]]</center>}}

	~~{{hidden\|Describe briefly how Taqman automated genotyping is used for allele detection. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|How are DNA microarrays used to identify drug disposition or responses?\|<center>[[Microsatellite instability]]</center>}}~~

	~~===UNIT 4===~~
	~~{{hidden\|Describe the procedure for submitting FFPE slides for KRAS for colorectal cancer.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Compare and contrast uniplex versus multiplex genotyping. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Compare and contrast conventional vs massively parallel sequencing. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is multiplex ligation-dependent ligation (MLPA)?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is fragment analysis?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Compare and contrast RT-PCR vs qRTPCR.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is MSI?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is methylation analysis?\|<center>[[Microsatellite instability]]</center>}}~~

	~~===UNIT 5===~~
	~~{{hidden\|What are the four test features required to be documented by the CLIA?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What are "in vitro diagnostics" vs "laboratory developed tests"?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What does validation mean? \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What are the four performance characteristics that need to be verified for FDA cleared/approved tests?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What are the six performance characteristics that need to be verified for FDA cleared LDTs or modified FDA cleared/approved tests?\|<center>[[Microsatellite instability]]</center>}}~~

	~~===UNIT 6===~~
	~~{{hidden\|List the components of a molecular pathology report.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Define analytical sensitivity and clinical sensitivity. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What should be said in a report of a molecular test on a patient for residual disease if no previous positive assay was confirmed?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Define ammended report versus addendum report.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Whose responsibility is it to sythesize the test results with other clinico-pathological information?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|How long are cytogenetic reports required to be kept by CAP?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is the recommended process to use test results if an assay is not yet validated for clinical use?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Give three examples of "grey areas" which warrant discretion of professionals involved to use a non-validated test?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What reference standard is available for gene nomenclature?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Create a table of the most common gene rearrangements associated with heme and soft tissue diseases. \|<center>[[Microsatellite instability]]</center>}}~~

	{{hidden\|What is a "DNA fingerprint" and what can it be used for?\|<center>[[A method that examines multiple areas of short tandem repeats to identify paternity, mosaicism, chimerism, and identity in forensics cases]]
	~~</center>}}~~


	==Robbins and Cotran Chapter 5 9th Edition:==		==Robbins and Cotran Chapter 5 9th Edition:==

Tate at 19:23, 14 May 2015

2015-05-14T19:23:11Z

← Older revision		Revision as of 19:23, 14 May 2015
Line 52:		Line 52:
	These are some questions I came up with that are plausible to me... let me know if they are out to lunch.		These are some questions I came up with that are plausible to me... let me know if they are out to lunch.

	==Molecular Pathology Rotation Notes==		==[[Molecular Pathology Rotation Notes]]==

	===UNIT 1===		===UNIT 1===
Line 231:		Line 231:
	{{hidden\|List some pros and cons of ALK IHC.\|[[Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control]]}}		{{hidden\|List some pros and cons of ALK IHC.\|[[Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control]]}}

	{{What is a positive count in the ALK-FISH?\|[[Signal split >2 probe diameters]]}}		{{hidden\|What is a positive count in the ALK-FISH?\|[[Signal split >2 probe diameters]]}}

	===CAP Molecular Diagnosis of AML===		===CAP Molecular Diagnosis of AML===
Line 241:		Line 241:
	{{hidden\|Give any three translocations identified in AML.\|[[t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA]]}}		{{hidden\|Give any three translocations identified in AML.\|[[t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA]]}}

	{{hidden\|What entities are fall under the AML, NOS classification?\|[[ AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis]]}}		{{hidden\|What entities are fall under the AML, NOS classification?\|[[AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis]]}}

			{{hidden\|List 2 genes which confer a poor prognostic impact vs 2 which confer a good prognostic impact.\|[[Poor: KIT, FLT3, Good: NPM1, CEBPA]]}}


			=== CAP Breast Cancer and Molecular ===

			{{Hidden\|List 3 patient and 4 tumour features that affect Prognosis and treatment.\|[[Patient: age, menstual status, comorbidities; Tumour factors: N status, LVI, size, grade]]}}

			{{hidden\|Describe the histological grading system used for breast cancer.\|[[Nuclear pleomorphism, mitoses, and mitotic index (each scored 1-3), with cumulative grade 1(score 3-5), grade 2(score 6-7), and grade 3 (score 8-9)]]}}

			{{hidden\|Describe the genomic grading system used for breast cancer.\|[[Low grade path (+1q, -16q), High grade (17q12, 11q13, nad 1p21-p25)]]}}

			{{hidden\|What defines a positive ER by IHC for the purpose of determining Tamoxifen therapy?\|[[>=1% of invasive tumour cells nuclear positivity]]}}

			{{hidden\|what defines a positive HER2 for the purpose of treatment with Herceptin?\|[[HER2 IHC >30% with complete membranous staining OR HER2/CEP17 >2.2]]}}

			{{hidden\|What are the indications for chemotherapy for breast cancer patients?\|[[Low expression of ER/PR, Grade 3 histology, Ki67>20%, 4+ nodes positive, +LVI, and tumour >5cm]}}

			{{hidden\|What are the indications for hormonal therapy alone?\|[[high expression of ER, Grade 1, Ki67>40%, Node negative, LVI not identified, and tumour 1-2cm]]}

			{{hidden\|What are the four categories of breast cancer using the molecular classification of gene expression?\|[[Luminal A, Luminal B, Basal, and Her2 OverExpression]]}}

			{{hidden\|What is the difference between unsupervised and supervised molecular classification of tumours?\|[[Supervised is based on seperating patients by clinical features (e.g. progression) and trying to identify common molecular characteristics within those groups. Unsupervised is the opposite, tumours are grouped by common molecular features and their behaviour examined based on these groups.]]}}

			{{hidden\|What are the four groups and list one gene for each used in the Oncotype Dx 21 Gene prognostic model.\|[[Invasion (Cathespin L2, Stromolysin), HER2 (Her2, GRB7), ER (BCL2, SCUBE2, ER, PR), Proliferation (Cyclin D1, Ki67, MYBL2, STK15, Survivin)]]}}

			{{hidden\|What are the features of Luminal A breast cancer?\|High ER/PR expression, low histological grade, low levels of proliferative genes, HER2neg, indolent clinical course, better prognosis, Tamoxifen responders, low recurrence score Oncotype Dx, minimal benefits of adjuvant chemotherapy.]]}}

			{{hidden\|What are the features of Luminal B breast cancer?\|low ER/PR expression (may be PR neg), over expression GFR(Her2 & EGFR), higher histological grade, more aggressive clinical course, worse prognosis, more likely positive lymph nodes, and high expression of proliferative genes (Ki67)]]}}

			{{hidden\|What are the features of Luminal B HER2\|[[ ER+, HER2+, agressive clinical course, decrease response to tamoxifen, may benefit from chemo and tamoxifen, increased recurrence risk Oncotype Dx Score, some may benefit form Herceptin+Chemo+Tamoxifen]]}}

			{{hidden\|What are the features of Her2 Enriched breast cancers?\|[[ GEP are ER neg, over expression of other genes in HER2 aplification, high proliferative index, increased probability of P53 mutation, high histological grade, younger age, agressive clinical course, Poor Px, good response to herceptin in combination with chemo, pathological complete response to chemo+herceptin]]}}


			{{hidden\|What are the features of Basal breast cancer?\|[[]]}}

← Older revision		Revision as of 13:29, 12 August 2015
Line 49:		Line 49:

	= [[Short answer questions submitted by Tate]]=		= [[Short answer questions submitted by Tate]]=

	~~== Short answer questions on genetics and molecular pathology. ==~~

	~~These are some questions I came up with that are plausible to me... let me know if they are out to lunch.~~

	~~==[[Molecular Pathology Rotation Notes]]==~~

	~~==[[Robbins and Cotran 9th Edition Questions]]==~~

	~~==[[Cytogenetics Review Questions]]==~~


	~~== Molecular Genetic Diagnosis==~~
	~~{{hidden\|List three basic molecular diagnostic techniques\|a. Karyotyping, b. Southern blot, c. Sanger DNA sequencing, d. Polymerase chain reaction}}~~


	~~===CAP Molecular Diagnosis of Lung Cancer===~~

	{{hidden\|List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration\|1. 100% of CML: BRR-ABL > Imatinib, 2. 20% of Lung Adenocarcinoma: EGFR > Erlotinib/Gefitinib, 3. 25% Infiltrative ductal carcinoma of breast HER2>Trastuzumab, 4. 50% of Melanoma, BRAF v600E > PLX4032, 5. 4% of Lung Adenocarcinoma: ALK > Crizotinib}}

	~~{{hidden\|List and describe 5 areas of Genetic characaterization of tumours for personalized medicine\|DNA mutations, DNA chromosomal alterations, mRNA and MiRNA profiling, Proteomics, DNA epigenetics}}~~

	~~{{hidden\|What fraction of Lung adenocarcinomas have no known detactable mutations\|42%}}~~

	~~{{hidden\|What are the three most common molecular alterations of Lung Adenocarcinoma\|KRAS 23%, EGFR 15%, TP53 5%}}~~

	~~{{hidden\|What is the two most common molecular alteration makes patients with EGFR mutations resistant to targetted therapies?\|KRAS (primary) and T790M (primary and acquired)}}~~

	~~{{hidden\|List two EGFR kinase inhibitors.\|Gefitinib/Iressa, Erlotinib/Tarceva}}~~

	~~{{hidden\|What are the three most common cancers associated with KRAS mutations?\|Pancreatic 90%, Colon 50%, Lung NSCLC 30%}}~~

	~~{{hidden\|Why don't KRAS + tumours respond to Anti EGFR therapies?\|KRAS is downstream from EGFR, so changing the function of EFGR would not have any effect on mutated KRAS}}~~

	~~{{hidden\|Explain the cost effectiveness of genetic testing for targetted therapies?\|Most molecular tests cost $200-1000, vs one month of targetted therapy $2000-10000/month}}~~

	{{hidden\|What are the three most common cancers associated with BRAF mutations?\|Melanoma 70%, Papillary Thyroid Carcinoma 50%, Ovarian serious carcinoma 30%, Colon cancer 10%, Hint Papillary architecture}}

	{{hidden\|Beta catenin/CTNNB1 expression is found with which histological pattern of lung adenocarcinoma?\|Low grade adenocarcinoma of fetal type, poor px, <40yo, and has glycogen rich glandular formations, may occur in FAP patients}}

	~~{{hidden\|What is the most common ALK rearrangement found in NSCLC?\|EML4-ALK (90% of the 13% of lung cancers found to due to ALK fusions)}}~~

	{{hidden\|List some pros and cons of ALK FISH.\|Pros: commercial FDA approved probes available, not too expensive, moderately easy to disseminate screening, clinically validated, and failed tests on poorly preserved tissues are not reported as negative. Cons: need fish lab expertise (including pathologist and PhD), can be tricky if genes are close}}

	{{hidden\|List some pros and cons of ALK IHC.\|Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control}}

	~~{{hidden\|What is a positive count in the ALK-FISH?\|Signal split >2 probe diameters}}~~

	~~===CAP Molecular Diagnosis of AML===~~

	~~{{hidden\|List 6 genes associated with Acute Myeloid Leukemia that have been identified by cloning translocation break points\|RUNX1, RUNX1T1, PML, CBFB, ETV6, MLL}}~~

	{{hidden\|List the 5 main categories of classification of Acute Myeloid Leukemia\|1. AML with recurrent genetic abnormalities, 2. AML with myelodysplasia-related changes, 3. Therapy related myeloid neoplasms, 4. AML, NOS, 5. Myeloid sarcoma}}

	~~{{hidden\|Give any three translocations identified in AML.\|t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA}}~~

	{{hidden\|What entities are fall under the AML, NOS classification?\|AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis}}

	~~{{hidden\|List 2 genes which confer a poor prognostic impact vs 2 which confer a good prognostic impact.\|Poor: KIT, FLT3, Good: NPM1, CEBPA}}~~


	~~=== CAP Breast Cancer and Molecular ===~~

	~~{{Hidden\|List 3 patient and 4 tumour features that affect Prognosis and treatment.\|Patient: age, menstual status, comorbidities; Tumour factors: N status, LVI, size, grade}}~~

	{{hidden\|Describe the histological grading system used for breast cancer.\|Nuclear pleomorphism, mitoses, and mitotic index (each scored 1-3), with cumulative grade 1(score 3-5), grade 2(score 6-7), and grade 3 (score 8-9)}}

	~~{{hidden\|Describe the genomic grading system used for breast cancer.\|Low grade path (+1q, -16q), High grade (17q12, 11q13, nad 1p21-p25)}}~~

	~~{{hidden\|What defines a positive ER by IHC for the purpose of determining Tamoxifen therapy?\|>=1% of invasive tumour cells nuclear positivity}}~~

	~~{{hidden\|what defines a positive HER2 for the purpose of treatment with Herceptin?\|HER2 IHC >30% with complete membranous staining OR HER2/CEP17 >2.2}}~~

	~~{{hidden\|What are the indications for chemotherapy for breast cancer patients?\|Low expression of ER/PR, Grade 3 histology, Ki67>20%, 4+ nodes positive, +LVI, and tumour >5cm]}}~~

	~~{{hidden\|What are the indications for hormonal therapy alone?\|high expression of ER, Grade 1, Ki67>40%, Node negative, LVI not identified, and tumour 1-2cm}}~~

	~~{{hidden\|What are the four categories of breast cancer using the molecular classification of gene expression?\|Luminal A, Luminal B, Basal, and Her2 OverExpression}}~~

	{{hidden\|What is the difference between unsupervised and supervised molecular classification of tumours?\|Supervised is based on seperating patients by clinical features (e.g. progression) and trying to identify common molecular characteristics within those groups. Unsupervised is the opposite, tumours are grouped by common molecular features and their behaviour examined based on these groups.}}

	{{hidden\|What are the four groups and list one gene for each used in the Oncotype Dx 21 Gene prognostic model.\|Invasion (Cathespin L2, Stromolysin), HER2 (Her2, GRB7), ER (BCL2, SCUBE2, ER, PR), Proliferation (Cyclin D1, Ki67, MYBL2, STK15, Survivin)}}

	{{hidden\|What are the features of Luminal A breast cancer?\|High ER/PR expression, low histological grade, low levels of proliferative genes, HER2neg, indolent clinical course, better prognosis, Tamoxifen responders, low recurrence score Oncotype Dx, minimal benefits of adjuvant chemotherapy.}}

	{{hidden\|What are the features of Luminal B breast cancer?\|low ER/PR expression (may be PR neg), over expression GFR(Her2 & EGFR), higher histological grade, more aggressive clinical course, worse prognosis, more likely positive lymph nodes, and high expression of proliferative genes (Ki67)}}

	{{hidden\|What are the features of Luminal B HER2\| ER+, HER2+, agressive clinical course, decrease response to tamoxifen, may benefit from chemo and tamoxifen, increased recurrence risk Oncotype Dx Score, some may benefit form Herceptin+Chemo+Tamoxifen}}

	{{hidden\|What are the features of Her2 Enriched breast cancers?\| GEP are ER neg, over expression of other genes in HER2 aplification, high proliferative index, increased probability of P53 mutation, high histological grade, younger age, agressive clinical course, Poor Px, good response to herceptin in combination with chemo, pathological complete response to chemo+herceptin}}


	~~{{hidden\|What are the features of Basal breast cancer?\|}}~~

← Older revision		Revision as of 14:20, 18 May 2015
Line 53:		Line 53:

	==[[Molecular Pathology Rotation Notes]]==		==[[Molecular Pathology Rotation Notes]]==

	~~===UNIT 1===~~

	~~{{hidden\|List three differences between DNA and RNA.\|[[DNA (double stranded, thymine, deoxyribose, more stable; RNA single stranded, ribose, uracil]]}}~~

	~~{{hidden\|What are the three stop codons?\|[UAA, UGA, UAG]]}}~~

	~~{{hidden\|Where does transcription begin?\|[[promoters at the 5' end before the coding region]]}}~~

	~~{{hidden\|List 2 enzymes necessary for transcription and their function. \|[[helicase, polymerase]]}}~~

	~~{{hidden\|List and describe three post transcription modifications of RNA.\|[[Splicing, cappping, 3'polyadenylation, ]]}}~~

	{{hidden\| Why is alternative splicing important?\|[[Using the basic construction blocks of coding sequences allows a large variety of recombinations, more efficient coding (e.g. creating functions to call))]]}}

	{{hidden\|List three differences between somatic and germline mutations. \|<center>[[Somatic: not passed on to progeny, only tumour or particular tissue cells with mutation, Germline: passed onto progeny, all cells have mutation * unless mosaicism or chimerism]]</center>}}

	{{hidden\|What is the difference between a missense and a non-sense mutation?\|<center>[[Missense the new base pair does not change the amino acid found in the protein at that location, non-sense changes the amino acid in the protein at that location]]</center>}}

	{{hidden\|Define a frameshift mutation. \|<center>[[deletion of a non-multiple of 3 which causes all further trinucleotide combinations to no longer code for the correct amino acid, often results in a premature stop codon]]</center>}}

	~~{{hidden\|Why are inversion mutations difficult to detect?\|<center>[[When the are smal, e.g. only a few base pairs]]</center>}}~~

	{{hidden\|Describe the potential sequelae of a translocation mutation. \|<center>[[when a segment on one chromosome is transferred to another, make a gene non-functional or can result in a fusion gene]]</center>}}

	~~===UNIT 2===~~
	~~{{hidden\|Translate the following: c.1524_1527delCGTA.\|<center>[[a small deletion of CGTA between the 1524 and 1527 base pairs]]</center>}}~~

	{{hidden\|List 5 features of SNPs.\|[[Most common DNA sequence variation in humans, must occur in >=1% of a particular population, frequency of SNPs varies by groups, but responsible for >90% of human genetic variation, an can be found in any region of genome]]}}

	{{hidden\|Define a regulatory SNP versus a synonymous SNP?\|[[Regulatory SNP: occur in non-coding regions e.g. promoters where they affect mRNA expression and stability, as occur in the splice site where can result in abnormal protein production]]}}

	{{hidden\|What is the difference between a microstalellite and a minisattelite?\|<center>[[Microsatellite = stretches of DNA with sequences of 2-4 base pairs repeated a few dozen times (STRP), minisatellite = variable number of tandem repeats 10-100bp in lenght]]</center>}}

	~~{{hidden\|Describe Hardy-Weinberg Equilibrium?\|<center>[[Mathematical probability function to describe allelic and genotype frequency in a random mating scenario]]</center>}}~~

	~~{{hidden\|What factors can disrupt the H-W equilibrium?\|<center>[[non random mating, migration, genetic drift, founder effects, mutation, natural selection]]</center>}}~~

	{{hidden\|What is linkage disequilibrium?\|<center>[[The closer two genes are together on the chromosome the more likely they are to be found toghether in a population, during meiosis some exchange of material happens between the two chromosomes]]</center>}}

	~~===UNIT 3===~~
	~~{{hidden\|What are the three major steps of PCR?\|<center>[[denaturing, primer annealing, strand extending]]</center>}}~~

	{{hidden\|What is the hallmark of PCR?\|<center>[[The cycling at different temperatures, in the presence of key reaction components to traget and exponentially amplify a specific DNA target sequence]]</center>}}

	{{hidden\|What factors affect the method of genotyping chosen?\|<center>[[throughput, type of variants that can be genotyped, equipment and costs, TAT, technical expertise, and multiplex ability]]</center>}}

	{{hidden\|Define sensitivity, specificity, positive predictive value and negative predictive value. \|<center>[[Sensitivity = probability of a positive test in a disease, specificity = probability of a negative dest in a non-diseased patient ]]</center>}}

	{{hidden\|Define reproduciblity and accuracy of an analytical test. \|<center>[[Reproducability = probability of the test repeatedly producing the same reults in the same person, Accuracy = the degree to which the observed genotype matches the true genotype]]</center>}}

	{{hidden\|Describe briefly Sanger sequencing.\|<center>[[DIdeoxynucleotides are used in a mix with deoxynucleotides, the Di*** terminate the chain, and so you get all possible lengths of chains so then you put them all in order and you can read (based on weight) which one is at each position]]</center>}}

	~~{{hidden\|Describe briefly how Taqman automated genotyping is used for allele detection. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|How are DNA microarrays used to identify drug disposition or responses?\|<center>[[Microsatellite instability]]</center>}}~~

	~~===UNIT 4===~~
	~~{{hidden\|Describe the procedure for submitting FFPE slides for KRAS for colorectal cancer.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Compare and contrast uniplex versus multiplex genotyping. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Compare and contrast conventional vs massively parallel sequencing. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is multiplex ligation-dependent ligation (MLPA)?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is fragment analysis?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Compare and contrast RT-PCR vs qRTPCR.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is MSI?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is methylation analysis?\|<center>[[Microsatellite instability]]</center>}}~~

	~~===UNIT 5===~~
	~~{{hidden\|What are the four test features required to be documented by the CLIA?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What are "in vitro diagnostics" vs "laboratory developed tests"?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What does validation mean? \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What are the four performance characteristics that need to be verified for FDA cleared/approved tests?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What are the six performance characteristics that need to be verified for FDA cleared LDTs or modified FDA cleared/approved tests?\|<center>[[Microsatellite instability]]</center>}}~~

	~~===UNIT 6===~~
	~~{{hidden\|List the components of a molecular pathology report.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Define analytical sensitivity and clinical sensitivity. \|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What should be said in a report of a molecular test on a patient for residual disease if no previous positive assay was confirmed?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Define ammended report versus addendum report.\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Whose responsibility is it to sythesize the test results with other clinico-pathological information?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|How long are cytogenetic reports required to be kept by CAP?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What is the recommended process to use test results if an assay is not yet validated for clinical use?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Give three examples of "grey areas" which warrant discretion of professionals involved to use a non-validated test?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|What reference standard is available for gene nomenclature?\|<center>[[Microsatellite instability]]</center>}}~~

	~~{{hidden\|Create a table of the most common gene rearrangements associated with heme and soft tissue diseases. \|<center>[[Microsatellite instability]]</center>}}~~

	{{hidden\|What is a "DNA fingerprint" and what can it be used for?\|<center>[[A method that examines multiple areas of short tandem repeats to identify paternity, mosaicism, chimerism, and identity in forensics cases]]
	~~</center>}}~~


	==Robbins and Cotran Chapter 5 9th Edition:==		==Robbins and Cotran Chapter 5 9th Edition:==

← Older revision		Revision as of 19:23, 14 May 2015
Line 52:		Line 52:
	These are some questions I came up with that are plausible to me... let me know if they are out to lunch.		These are some questions I came up with that are plausible to me... let me know if they are out to lunch.

	==Molecular Pathology Rotation Notes==		==[[Molecular Pathology Rotation Notes]]==

	===UNIT 1===		===UNIT 1===
Line 231:		Line 231:
	{{hidden\|List some pros and cons of ALK IHC.\|[[Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control]]}}		{{hidden\|List some pros and cons of ALK IHC.\|[[Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control]]}}

	{{What is a positive count in the ALK-FISH?\|[[Signal split >2 probe diameters]]}}		{{hidden\|What is a positive count in the ALK-FISH?\|[[Signal split >2 probe diameters]]}}

	===CAP Molecular Diagnosis of AML===		===CAP Molecular Diagnosis of AML===
Line 241:		Line 241:
	{{hidden\|Give any three translocations identified in AML.\|[[t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA]]}}		{{hidden\|Give any three translocations identified in AML.\|[[t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA]]}}

	{{hidden\|What entities are fall under the AML, NOS classification?\|[[ AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis]]}}		{{hidden\|What entities are fall under the AML, NOS classification?\|[[AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis]]}}

			{{hidden\|List 2 genes which confer a poor prognostic impact vs 2 which confer a good prognostic impact.\|[[Poor: KIT, FLT3, Good: NPM1, CEBPA]]}}


			=== CAP Breast Cancer and Molecular ===

			{{Hidden\|List 3 patient and 4 tumour features that affect Prognosis and treatment.\|[[Patient: age, menstual status, comorbidities; Tumour factors: N status, LVI, size, grade]]}}

			{{hidden\|Describe the histological grading system used for breast cancer.\|[[Nuclear pleomorphism, mitoses, and mitotic index (each scored 1-3), with cumulative grade 1(score 3-5), grade 2(score 6-7), and grade 3 (score 8-9)]]}}

			{{hidden\|Describe the genomic grading system used for breast cancer.\|[[Low grade path (+1q, -16q), High grade (17q12, 11q13, nad 1p21-p25)]]}}

			{{hidden\|What defines a positive ER by IHC for the purpose of determining Tamoxifen therapy?\|[[>=1% of invasive tumour cells nuclear positivity]]}}

			{{hidden\|what defines a positive HER2 for the purpose of treatment with Herceptin?\|[[HER2 IHC >30% with complete membranous staining OR HER2/CEP17 >2.2]]}}

			{{hidden\|What are the indications for chemotherapy for breast cancer patients?\|[[Low expression of ER/PR, Grade 3 histology, Ki67>20%, 4+ nodes positive, +LVI, and tumour >5cm]}}

			{{hidden\|What are the indications for hormonal therapy alone?\|[[high expression of ER, Grade 1, Ki67>40%, Node negative, LVI not identified, and tumour 1-2cm]]}

			{{hidden\|What are the four categories of breast cancer using the molecular classification of gene expression?\|[[Luminal A, Luminal B, Basal, and Her2 OverExpression]]}}

			{{hidden\|What is the difference between unsupervised and supervised molecular classification of tumours?\|[[Supervised is based on seperating patients by clinical features (e.g. progression) and trying to identify common molecular characteristics within those groups. Unsupervised is the opposite, tumours are grouped by common molecular features and their behaviour examined based on these groups.]]}}

			{{hidden\|What are the four groups and list one gene for each used in the Oncotype Dx 21 Gene prognostic model.\|[[Invasion (Cathespin L2, Stromolysin), HER2 (Her2, GRB7), ER (BCL2, SCUBE2, ER, PR), Proliferation (Cyclin D1, Ki67, MYBL2, STK15, Survivin)]]}}

			{{hidden\|What are the features of Luminal A breast cancer?\|High ER/PR expression, low histological grade, low levels of proliferative genes, HER2neg, indolent clinical course, better prognosis, Tamoxifen responders, low recurrence score Oncotype Dx, minimal benefits of adjuvant chemotherapy.]]}}

			{{hidden\|What are the features of Luminal B breast cancer?\|low ER/PR expression (may be PR neg), over expression GFR(Her2 & EGFR), higher histological grade, more aggressive clinical course, worse prognosis, more likely positive lymph nodes, and high expression of proliferative genes (Ki67)]]}}

			{{hidden\|What are the features of Luminal B HER2\|[[ ER+, HER2+, agressive clinical course, decrease response to tamoxifen, may benefit from chemo and tamoxifen, increased recurrence risk Oncotype Dx Score, some may benefit form Herceptin+Chemo+Tamoxifen]]}}

			{{hidden\|What are the features of Her2 Enriched breast cancers?\|[[ GEP are ER neg, over expression of other genes in HER2 aplification, high proliferative index, increased probability of P53 mutation, high histological grade, younger age, agressive clinical course, Poor Px, good response to herceptin in combination with chemo, pathological complete response to chemo+herceptin]]}}


			{{hidden\|What are the features of Basal breast cancer?\|[[]]}}

← Older revision		Revision as of 14:22, 19 May 2015
Line 57:		Line 57:


	=== Molecular Genetic Diagnosis===		== Molecular Genetic Diagnosis==
	{{hidden\|List three basic molecular diagnostic techniques\|[[a. Karyotyping, b. Southern blot, c. Sanger DNA sequencing, d. Polymerase chain reaction]]}}		{{hidden\|List three basic molecular diagnostic techniques\|[[a. Karyotyping, b. Southern blot, c. Sanger DNA sequencing, d. Polymerase chain reaction}}


	===CAP Molecular Diagnosis of Lung Cancer===		===CAP Molecular Diagnosis of Lung Cancer===

	{{hidden\|List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration\|[[1. 100% of CML: BRR-ABL > Imatinib, 2. 20% of Lung Adenocarcinoma: EGFR > Erlotinib/Gefitinib, 3. 25% Infiltrative ductal carcinoma of breast HER2>Trastuzumab, 4. 50% of Melanoma, BRAF v600E > PLX4032, 5. 4% of Lung Adenocarcinoma: ALK > Crizotinib]]}}		{{hidden\|List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration\|1. 100% of CML: BRR-ABL > Imatinib, 2. 20% of Lung Adenocarcinoma: EGFR > Erlotinib/Gefitinib, 3. 25% Infiltrative ductal carcinoma of breast HER2>Trastuzumab, 4. 50% of Melanoma, BRAF v600E > PLX4032, 5. 4% of Lung Adenocarcinoma: ALK > Crizotinib}}

	{{hidden\|List and describe 5 areas of Genetic characaterization of tumours for personalized medicine\|[[DNA mutations, DNA chromosomal alterations, mRNA and MiRNA profiling, Proteomics, DNA epigenetics]]}}		{{hidden\|List and describe 5 areas of Genetic characaterization of tumours for personalized medicine\|DNA mutations, DNA chromosomal alterations, mRNA and MiRNA profiling, Proteomics, DNA epigenetics}}

	{{hidden\|What fraction of Lung adenocarcinomas have no known detactable mutations\|[[42%]]}}		{{hidden\|What fraction of Lung adenocarcinomas have no known detactable mutations\|42%}}

	{{hidden\|What are the three most common molecular alterations of Lung Adenocarcinoma\|[[KRAS 23%, EGFR 15%, TP53 5%]]}}		{{hidden\|What are the three most common molecular alterations of Lung Adenocarcinoma\|KRAS 23%, EGFR 15%, TP53 5%}}

	{{hidden\|What is the two most common molecular alteration makes patients with EGFR mutations resistant to targetted therapies?\|[[KRAS (primary) and T790M (primary and acquired)]]}}		{{hidden\|What is the two most common molecular alteration makes patients with EGFR mutations resistant to targetted therapies?\|KRAS (primary) and T790M (primary and acquired)}}

	{{hidden\|List two EGFR kinase inhibitors.\|[[Gefitinib/Iressa, Erlotinib/Tarceva]]}}		{{hidden\|List two EGFR kinase inhibitors.\|Gefitinib/Iressa, Erlotinib/Tarceva}}

	{{hidden\|What are the three most common cancers associated with KRAS mutations?\|[[Pancreatic 90%, Colon 50%, Lung NSCLC 30%]]}}		{{hidden\|What are the three most common cancers associated with KRAS mutations?\|Pancreatic 90%, Colon 50%, Lung NSCLC 30%}}

	{{hidden\|Why don't KRAS + tumours respond to Anti EGFR therapies?\|[[KRAS is downstream from EGFR, so changing the function of EFGR would not have any effect on mutated KRAS]]}}		{{hidden\|Why don't KRAS + tumours respond to Anti EGFR therapies?\|KRAS is downstream from EGFR, so changing the function of EFGR would not have any effect on mutated KRAS}}

	{{hidden\|Explain the cost effectiveness of genetic testing for targetted therapies?\|[[Most molecular tests cost $200-1000, vs one month of targetted therapy $2000-10000/month]]}}		{{hidden\|Explain the cost effectiveness of genetic testing for targetted therapies?\|Most molecular tests cost $200-1000, vs one month of targetted therapy $2000-10000/month}}

	{{hidden\|What are the three most common cancers associated with BRAF mutations?\|[[Melanoma 70%, Papillary Thyroid Carcinoma 50%, Ovarian serious carcinoma 30%, Colon cancer 10%, Hint Papillary architecture]]}}		{{hidden\|What are the three most common cancers associated with BRAF mutations?\|Melanoma 70%, Papillary Thyroid Carcinoma 50%, Ovarian serious carcinoma 30%, Colon cancer 10%, Hint Papillary architecture}}

	{{hidden\|Beta catenin/CTNNB1 expression is found with which histological pattern of lung adenocarcinoma?\|[[Low grade adenocarcinoma of fetal type, poor px, <40yo, and has glycogen rich glandular formations, may occur in FAP patients]]}}		{{hidden\|Beta catenin/CTNNB1 expression is found with which histological pattern of lung adenocarcinoma?\|Low grade adenocarcinoma of fetal type, poor px, <40yo, and has glycogen rich glandular formations, may occur in FAP patients}}

	{{hidden\|What is the most common ALK rearrangement found in NSCLC?\|[[EML4-ALK (90% of the 13% of lung cancers found to due to ALK fusions)]]}}		{{hidden\|What is the most common ALK rearrangement found in NSCLC?\|EML4-ALK (90% of the 13% of lung cancers found to due to ALK fusions)}}

	{{hidden\|List some pros and cons of ALK FISH.\|[[Pros: commercial FDA approved probes available, not too expensive, moderately easy to disseminate screening, clinically validated, and failed tests on poorly preserved tissues are not reported as negative. Cons: need fish lab expertise (including pathologist and PhD), can be tricky if genes are close]]}}		{{hidden\|List some pros and cons of ALK FISH.\|Pros: commercial FDA approved probes available, not too expensive, moderately easy to disseminate screening, clinically validated, and failed tests on poorly preserved tissues are not reported as negative. Cons: need fish lab expertise (including pathologist and PhD), can be tricky if genes are close}}

	{{hidden\|List some pros and cons of ALK IHC.\|[[Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control]]}}		{{hidden\|List some pros and cons of ALK IHC.\|Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control}}

	{{hidden\|What is a positive count in the ALK-FISH?\|[[Signal split >2 probe diameters]]}}		{{hidden\|What is a positive count in the ALK-FISH?\|Signal split >2 probe diameters}}

	===CAP Molecular Diagnosis of AML===		===CAP Molecular Diagnosis of AML===

	{{hidden\|List 6 genes associated with Acute Myeloid Leukemia that have been identified by cloning translocation break points\|[[RUNX1, RUNX1T1, PML, CBFB, ETV6, MLL]]}}		{{hidden\|List 6 genes associated with Acute Myeloid Leukemia that have been identified by cloning translocation break points\|RUNX1, RUNX1T1, PML, CBFB, ETV6, MLL}}

	{{hidden\|List the 5 main categories of classification of Acute Myeloid Leukemia\|[[1. AML with recurrent genetic abnormalities, 2. AML with myelodysplasia-related changes, 3. Therapy related myeloid neoplasms, 4. AML, NOS, 5. Myeloid sarcoma]]}}		{{hidden\|List the 5 main categories of classification of Acute Myeloid Leukemia\|1. AML with recurrent genetic abnormalities, 2. AML with myelodysplasia-related changes, 3. Therapy related myeloid neoplasms, 4. AML, NOS, 5. Myeloid sarcoma}}

	{{hidden\|Give any three translocations identified in AML.\|[[t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA]]}}		{{hidden\|Give any three translocations identified in AML.\|t(8,21), inv (16), t(15,17), t(9,11), t(6,9), inv(3), t(1,22), mutated NPM1, mutated CEBPA}}

	{{hidden\|What entities are fall under the AML, NOS classification?\|[[AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis]]}}		{{hidden\|What entities are fall under the AML, NOS classification?\|AML with minimal differentiation, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monoblastic/monocytic leukemia, Acute erythroid leukemias (pure erythroid, erythroleukemia, erythroid/myeloid), Acute Megakaryoblastic leukemia, Acute basophilic leukemia, Acte panmyelosis with myelofibrosis}}

	{{hidden\|List 2 genes which confer a poor prognostic impact vs 2 which confer a good prognostic impact.\|[[Poor: KIT, FLT3, Good: NPM1, CEBPA]]}}		{{hidden\|List 2 genes which confer a poor prognostic impact vs 2 which confer a good prognostic impact.\|Poor: KIT, FLT3, Good: NPM1, CEBPA}}


	=== CAP Breast Cancer and Molecular ===		=== CAP Breast Cancer and Molecular ===

	{{Hidden\|List 3 patient and 4 tumour features that affect Prognosis and treatment.\|[[Patient: age, menstual status, comorbidities; Tumour factors: N status, LVI, size, grade]]}}		{{Hidden\|List 3 patient and 4 tumour features that affect Prognosis and treatment.\|Patient: age, menstual status, comorbidities; Tumour factors: N status, LVI, size, grade}}

	{{hidden\|Describe the histological grading system used for breast cancer.\|[[Nuclear pleomorphism, mitoses, and mitotic index (each scored 1-3), with cumulative grade 1(score 3-5), grade 2(score 6-7), and grade 3 (score 8-9)]]}}		{{hidden\|Describe the histological grading system used for breast cancer.\|Nuclear pleomorphism, mitoses, and mitotic index (each scored 1-3), with cumulative grade 1(score 3-5), grade 2(score 6-7), and grade 3 (score 8-9)}}

	{{hidden\|Describe the genomic grading system used for breast cancer.\|[[Low grade path (+1q, -16q), High grade (17q12, 11q13, nad 1p21-p25)]]}}		{{hidden\|Describe the genomic grading system used for breast cancer.\|Low grade path (+1q, -16q), High grade (17q12, 11q13, nad 1p21-p25)}}

	{{hidden\|What defines a positive ER by IHC for the purpose of determining Tamoxifen therapy?\|[[>=1% of invasive tumour cells nuclear positivity]]}}		{{hidden\|What defines a positive ER by IHC for the purpose of determining Tamoxifen therapy?\|>=1% of invasive tumour cells nuclear positivity}}

	{{hidden\|what defines a positive HER2 for the purpose of treatment with Herceptin?\|[[HER2 IHC >30% with complete membranous staining OR HER2/CEP17 >2.2]]}}		{{hidden\|what defines a positive HER2 for the purpose of treatment with Herceptin?\|HER2 IHC >30% with complete membranous staining OR HER2/CEP17 >2.2}}

	{{hidden\|What are the indications for chemotherapy for breast cancer patients?\|[[Low expression of ER/PR, Grade 3 histology, Ki67>20%, 4+ nodes positive, +LVI, and tumour >5cm]}}		{{hidden\|What are the indications for chemotherapy for breast cancer patients?\|Low expression of ER/PR, Grade 3 histology, Ki67>20%, 4+ nodes positive, +LVI, and tumour >5cm]}}

	{{hidden\|What are the indications for hormonal therapy alone?\|[[high expression of ER, Grade 1, Ki67>40%, Node negative, LVI not identified, and tumour 1-2cm]]}		{{hidden\|What are the indications for hormonal therapy alone?\|high expression of ER, Grade 1, Ki67>40%, Node negative, LVI not identified, and tumour 1-2cm}}

	{{hidden\|What are the four categories of breast cancer using the molecular classification of gene expression?\|[[Luminal A, Luminal B, Basal, and Her2 OverExpression]]}}		{{hidden\|What are the four categories of breast cancer using the molecular classification of gene expression?\|Luminal A, Luminal B, Basal, and Her2 OverExpression}}

	{{hidden\|What is the difference between unsupervised and supervised molecular classification of tumours?\|[[Supervised is based on seperating patients by clinical features (e.g. progression) and trying to identify common molecular characteristics within those groups. Unsupervised is the opposite, tumours are grouped by common molecular features and their behaviour examined based on these groups.]]}}		{{hidden\|What is the difference between unsupervised and supervised molecular classification of tumours?\|Supervised is based on seperating patients by clinical features (e.g. progression) and trying to identify common molecular characteristics within those groups. Unsupervised is the opposite, tumours are grouped by common molecular features and their behaviour examined based on these groups.}}

	{{hidden\|What are the four groups and list one gene for each used in the Oncotype Dx 21 Gene prognostic model.\|[[Invasion (Cathespin L2, Stromolysin), HER2 (Her2, GRB7), ER (BCL2, SCUBE2, ER, PR), Proliferation (Cyclin D1, Ki67, MYBL2, STK15, Survivin)]]}}		{{hidden\|What are the four groups and list one gene for each used in the Oncotype Dx 21 Gene prognostic model.\|Invasion (Cathespin L2, Stromolysin), HER2 (Her2, GRB7), ER (BCL2, SCUBE2, ER, PR), Proliferation (Cyclin D1, Ki67, MYBL2, STK15, Survivin)}}

	{{hidden\|What are the features of Luminal A breast cancer?\|High ER/PR expression, low histological grade, low levels of proliferative genes, HER2neg, indolent clinical course, better prognosis, Tamoxifen responders, low recurrence score Oncotype Dx, minimal benefits of adjuvant chemotherapy.]]}}		{{hidden\|What are the features of Luminal A breast cancer?\|High ER/PR expression, low histological grade, low levels of proliferative genes, HER2neg, indolent clinical course, better prognosis, Tamoxifen responders, low recurrence score Oncotype Dx, minimal benefits of adjuvant chemotherapy.}}

	{{hidden\|What are the features of Luminal B breast cancer?\|low ER/PR expression (may be PR neg), over expression GFR(Her2 & EGFR), higher histological grade, more aggressive clinical course, worse prognosis, more likely positive lymph nodes, and high expression of proliferative genes (Ki67)]]}}		{{hidden\|What are the features of Luminal B breast cancer?\|low ER/PR expression (may be PR neg), over expression GFR(Her2 & EGFR), higher histological grade, more aggressive clinical course, worse prognosis, more likely positive lymph nodes, and high expression of proliferative genes (Ki67)}}

	{{hidden\|What are the features of Luminal B HER2\|[[ ER+, HER2+, agressive clinical course, decrease response to tamoxifen, may benefit from chemo and tamoxifen, increased recurrence risk Oncotype Dx Score, some may benefit form Herceptin+Chemo+Tamoxifen]]}}		{{hidden\|What are the features of Luminal B HER2\| ER+, HER2+, agressive clinical course, decrease response to tamoxifen, may benefit from chemo and tamoxifen, increased recurrence risk Oncotype Dx Score, some may benefit form Herceptin+Chemo+Tamoxifen}}

	{{hidden\|What are the features of Her2 Enriched breast cancers?\|[[ GEP are ER neg, over expression of other genes in HER2 aplification, high proliferative index, increased probability of P53 mutation, high histological grade, younger age, agressive clinical course, Poor Px, good response to herceptin in combination with chemo, pathological complete response to chemo+herceptin]]}}		{{hidden\|What are the features of Her2 Enriched breast cancers?\| GEP are ER neg, over expression of other genes in HER2 aplification, high proliferative index, increased probability of P53 mutation, high histological grade, younger age, agressive clinical course, Poor Px, good response to herceptin in combination with chemo, pathological complete response to chemo+herceptin}}


	{{hidden\|What are the features of Basal breast cancer?\|~~[[]]~~}}		{{hidden\|What are the features of Basal breast cancer?\|}}